

Special Issue

HIV Protease

Message from the Guest Editor

HIV-1 protease remains a target for the treatment of those living with HIV-1 infection. Until vaccines are developed, and latent infections can be overcome, the continued development of novel inhibitors and research into the mechanism of maturation and co-evolution of HIV-1 protease are essential for the management of viral loads and prevention of maturation of infectious virus particles. Research papers, perspectives, and review articles exploring/summarizing the development of novel inhibitors, drug resistance inhibitor development, multifunctional inhibitors, structural and dynamic studies, co-evolution of protease with other viral proteins, and comparative studies of resistance mechanisms from various subtypes are invited to contribute to this Special Issue.

Guest Editor

Prof. Dr. Gail E. Fanucci

Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

Deadline for manuscript submissions

closed (30 June 2025)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/201843

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).